Author, as appears in the article.: de Pablo-Miro, Mar; Pujol-Ruiz, Sergi; Iftimie, Simona; Arenas-Miras, Maria del Mar; Lopez-Montesinos, Inmaculada; Duran-Jorda, Xavier; Angles, Albert; Grau, Santiago; Horcajada, Juan P.;
Department: Medicina i Cirurgia
URV's Author/s: Iftimie Iftimie, Simona Mihaela
Keywords: Therapy Once-weekly dalbavancin Multidrug-resistant gram-positive cocci Mortality Methicillin-resistant staphylococci Hospital stay Gram-positive Effectiveness Dalbavancin Complicated skin
Abstract: Dalbavancin is a new antibiotic that is effective against Gram-positive microorganisms, including methicillin-resistant Staphylococci, and offers the possibility of administering intravenous therapy once weekly in an ambulatory setting. We conducted a multicenter observational case-control study, comparing all patients who received dalbavancin (cases) with hospitalized patients who were treated instead with daptomycin, linezolid or vancomycin (controls), based on clinical diagnosis, main microorganism involved, and age. The primary outcome was the length of hospital stay after starting the study antimicrobial. Secondary outcomes were 7-day and 30-day efficacy, 30-day mortality, 90-day recurrence, 90-day and 6-month hospitalization, presence of adverse events and healthcare-associated infections; 161 patients (44 cases and 117 controls) were included. Bivariate analysis showed that dalbavancin reduced the total length of hospital stay (p < 0.001), with fewer 90-day recurrences (p = 0.005), 6-month hospitalizations related to the same infection (p = 0.004) and non-related hospitalizations (p = 0.035). Multivariate analyses showed that length of hospital stay was significantly shorter in patients treated with dalbavancin (-12.05 days 95% CI [-17.00, -7.11], p < 0.001), and 30-day efficacy was higher in the dalbavancin group (OR 2.62 95% CI [1.07, 6.37], p = 0.034). Although sample size of the study may be a limitation, we can conclude that Dalbavancin is a useful antimicrobial drug against Gram-positive infections, including multidrug-resistant pathogens, and allows for a remarkable reduction in length of hospital stay with greater 30-day efficacy.
Thematic Areas: Pharmacology, toxicology and pharmaceutics (miscellaneous) Pharmacology, toxicology and pharmaceutics (all) Pharmacology (medical) Pharmacology & pharmacy Microbiology (medical) Microbiology Infectious diseases General pharmacology, toxicology and pharmaceutics Engenharias ii Biochemistry
licence for use: https://creativecommons.org/licenses/by/3.0/es/
Author's mail: simonamihaela.iftime@urv.cat
Author identifier: 0000-0003-0714-8414
Record's date: 2024-07-27
Papper version: info:eu-repo/semantics/publishedVersion
Link to the original source: https://www.mdpi.com/2079-6382/10/11/1296
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Papper original source: Antibiotics. 10 (11):
APA: de Pablo-Miro, Mar; Pujol-Ruiz, Sergi; Iftimie, Simona; Arenas-Miras, Maria del Mar; Lopez-Montesinos, Inmaculada; Duran-Jorda, Xavier; Angles, Albert (2021). Comparative Analysis of Dalbavancin versus Other Antimicrobial Options for Gram-Positive Cocci Infections: Effectiveness, Hospital Stay and Mortality. Antibiotics, 10(11), -. DOI: 10.3390/antibiotics10111296
Article's DOI: 10.3390/antibiotics10111296
Entity: Universitat Rovira i Virgili
Journal publication year: 2021
Publication Type: Journal Publications
Repositori URV